FDA Approved 2010 GHRH Analogue · 44 AA HIV Lipodystrophy

Tesamorelin

EGRIFTA · EGRIFTA WR · TH9507 · Trans-3-Hexenoyl GHRH

"The most clinically proven GHRH analogue for visceral fat. FDA approved with two Phase III RCTs behind it. The DPP-4 resistant modification makes it more durable than natural GHRH — and the fat loss data is unusually specific: visceral fat only, not subcutaneous."

Structure
44 AA · Trans-3-hexenoyl N-terminus
FDA Approved
2010 · EGRIFTA · HIV lipodystrophy
VAT reduction
15–20% over 26 weeks
Route
SubQ daily · 2mg
WADA
Prohibited
Origin & Background

The DPP-4 resistant GHRH

Tesamorelin is a 44 amino acid synthetic analogue of human GHRH, developed by Theratechnologies and approved by the FDA in 2010 as EGRIFTA — the first and only approved treatment for HIV-associated lipodystrophy (excess abdominal fat caused by antiretroviral therapy). A new weekly formulation, EGRIFTA WR, received FDA approval in March 2025.

The key structural innovation is the addition of a trans-3-hexenoic acid group to the N-terminus of the GHRH molecule. This modification protects the peptide from degradation by dipeptidyl peptidase 4 (DPP-4) — the enzyme that rapidly breaks down natural GHRH in the bloodstream. The result is a more durable, more potent GHRH signal than the natural molecule can sustain.

Two pivotal Phase III randomised controlled trials involving 740 HIV patients demonstrated tesamorelin reduced visceral adipose tissue (VAT) by 15–20% over 26 weeks — a selective effect on deep abdominal fat rather than subcutaneous fat. This selectivity is clinically significant because visceral fat is the metabolically dangerous depot associated with cardiovascular disease, insulin resistance, and inflammation.

Key advantage over sermorelin: Tesamorelin is 44 amino acids (the full active length of GHRH) vs sermorelin's 29 amino acids. The DPP-4 resistance makes it more stable and potent in vivo. It has superior Phase III RCT evidence for visceral fat specifically — a more targeted body composition effect than the broader anti-ageing claims of sermorelin.

Science & Mechanism

Visceral fat — targeted lipolysis

Mechanism of Action

1
DPP-4 resistance: The trans-3-hexenoyl N-terminal modification blocks DPP-4 cleavage — the major enzyme that degrades GHRH in plasma. This extends the effective half-life well beyond natural GHRH, allowing sustained pituitary stimulation from a once-daily injection.
2
Pituitary GHRHR binding: Tesamorelin binds GHRH receptors on pituitary somatotrophs with similar affinity to endogenous GHRH, stimulating pulsatile GH release while preserving somatostatin feedback regulation.
3
Selective visceral lipolysis: Elevated GH drives lipolysis preferentially in visceral adipose tissue over subcutaneous fat — the mechanism is not fully elucidated but visceral adipocytes have higher GH receptor density and greater sensitivity to GH-driven lipolysis.
4
IGF-1 and metabolic effects: GH elevation drives hepatic IGF-1 production, improving lean mass, lipid profiles (reduced triglycerides, improved HDL) and potentially insulin sensitivity — though tesamorelin can also increase insulin resistance acutely.
5
Emerging NAFLD application: A 2023 clinical trial in HIV patients with non-alcoholic fatty liver disease showed tesamorelin reduced liver fat content and prevented fibrosis progression — an emerging application beyond lipodystrophy.
Community Voices

What people report

Anecdotal ReportNot medical evidence · Individual experience

"The visceral fat reduction was the most targeted effect I've had from any peptide. My waist came down without losing size elsewhere. IGF-1 went to 280 ng/mL — had to dial back the dose. Sleep quality improved noticeably in the first month."

Male, 48, using compounded tesamorelin off-label for metabolic optimisation. The selectivity for visceral fat is the most consistently reported advantage over other GH secretagogues — users who've tried multiple note this specificity as its defining characteristic.

Anecdotal ReportNot medical evidence · Individual experience

"Prescribed by my functional medicine doctor after a DEXA showing high visceral fat. Six months in — waist down 4 inches, triglycerides halved. The water retention was a problem at 2mg so we dropped to 1mg and it resolved. Most expensive peptide I've used but the evidence is real."

Female, 54, using FDA-approved EGRIFTA off-label. The cost point is a genuine barrier — pharmaceutical tesamorelin is significantly more expensive than compounded alternatives. Insurance rarely covers off-label use.

Benefits & Evidence

What the data shows

🔥
Visceral fat reduction — selective
Phase III RCTs (n=740 HIV patients) showed 15–20% VAT reduction over 26 weeks. Effect is specific to visceral fat — subcutaneous fat is largely unaffected. This selectivity makes it uniquely suited to addressing metabolic syndrome and cardiovascular risk driven by visceral adiposity.
● Strong — two Phase III RCTs · FDA approved
💉
Lipid profile improvement
Phase III trials showed significant reductions in triglycerides and improvements in HDL cholesterol alongside VAT reduction. The combination of visceral fat loss and lipid improvement addresses key cardiovascular risk factors.
● Strong — Phase III data
🫀
NAFLD / liver fat reduction
2023 clinical trial in HIV patients with NAFLD: tesamorelin reduced liver fat content and prevented hepatic inflammation and fibrosis progression. A Phase II trial in non-HIV NAFLD patients is ongoing. Emerging but potentially significant application.
● Emerging — Phase II data, HIV population
💪
Lean mass and body composition
As a GHRH analogue driving GH and IGF-1, tesamorelin produces modest lean mass gains alongside fat loss — though this is secondary to the visceral fat effect. Body composition improvements are consistent across trials.
● Moderate — secondary endpoint in trials
Safety First

Risks & considerations

⚠️
Best-characterised GHRH analogue safety profile. Tesamorelin has the most comprehensive safety database of any GHRH analogue — 740 patients in Phase III trials. It retains the class risks of GH axis stimulation (water retention, insulin resistance, IGF-1 elevation) but these are well-characterised and manageable with monitoring.
Mild
Injection site reactions — erythema, pruritus, pain. Common, self-limiting. EGRIFTA WR's lower injection volume reduces this significantly.
Moderate
Water retention and joint pain — arthralgia and peripheral oedema occur in 10–18% of users. Dose-dependent, usually manageable with dose reduction.
Moderate
Insulin resistance / glucose elevation — GH acutely impairs insulin sensitivity. Phase III data showed increased risk of pre-diabetes in some patients. Monitor fasting glucose and HbA1c throughout.
Moderate
Elevated IGF-1 above normal range — occurs in a proportion of patients. Keep IGF-1 within age-appropriate reference ranges. Reduce dose if IGF-1 exceeds upper limit of normal.
Serious
Anti-tesamorelin antibodies — develop in 56% of patients at 26 weeks. Cross-reactivity with endogenous GHRH observed in 60% of antibody-positive patients. Clinical significance is unclear — efficacy was maintained — but represents an unknown long-term risk.
Serious
Contraindicated in active malignancy — GH stimulation is contraindicated with any active cancer. Hydrocephaly in rodent offspring — avoid in pregnancy entirely.

⚠ Key Warnings

Effects reverse on cessation — tesamorelin is maintenance therapy. VAT returns to near-baseline within months of stopping. This must be factored into any long-term decision.
WADA prohibited at all times for competitive athletes.
Monitor IGF-1, fasting glucose, HbA1c every 3 months. Antibody development is common — clinical implications are still being studied.
Compounded tesamorelin quality varies significantly. The pharmaceutical product (EGRIFTA WR) offers the highest assurance but at significantly higher cost.
Synergy Stack

Nutrients, Supplements & Exercise

Tesamorelin's primary effect is visceral fat reduction via GH/IGF-1. Synergies focus on protecting insulin sensitivity (its main metabolic risk), maximising fat oxidation, and supporting the lean mass preservation that comes with GH elevation.

💊 Nutrients & Supplements
Protein (1.6–2g/kg/day)
With every meal
Strong evidence
GH and IGF-1 drive protein synthesis — adequate protein provides the amino acid substrate needed to preserve lean mass during the visceral fat reduction protocol.
Berberine
500mg 2x/day with meals
Moderate evidence
Tesamorelin can impair insulin sensitivity — berberine's AMPK activation improves glucose metabolism and insulin signalling, counteracting this risk without blunting GH's lipolytic effect.
Omega-3 (EPA/DHA)
3g/day
Strong evidence
Reduces triglycerides independently — additive with tesamorelin's documented triglyceride-lowering effect. Also reduces systemic inflammation associated with visceral adiposity.
Avoid carbs before injection
Fast 2–3h before bedtime dose
Strong evidence
Elevated insulin blunts GH pulse amplitude. Injecting in a low-insulin state (fasted or 2–3h post-meal) maximises the GHRH stimulus and resulting GH/IGF-1 elevation.
🏃 Exercise & Lifestyle
Zone 2 cardio 3–4x/week
Zone 2 (60–70% max HR) preferentially oxidises visceral fat and improves insulin sensitivity — directly complementing tesamorelin's two primary targets. Most effective fat-burning exercise for metabolic syndrome.
Resistance training
Builds lean mass that GH/IGF-1 supports. Compound lifts (squat, deadlift, press) generate the greatest GH pulse of any exercise type — stacking with the nightly tesamorelin injection creates additive GH stimulation.
Morning light and consistent sleep timing
GH release is circadian — consistent sleep timing maximises the nightly GH pulse tesamorelin stimulates. Morning light exposure sets the circadian clock and improves cortisol/GH rhythm.
⏱ Timing & Protocol Notes
Tesamorelin 2mg SubQ nightly, fasted. EGRIFTA WR allows once-weekly reconstitution. Monitor VAT reduction via waist circumference and ideally DEXA or MRI at baseline and 6 months. Monitor IGF-1, fasting glucose and HbA1c every 3 months. If VAT hasn't improved by 26 weeks, discontinuation is reasonable. Effects reverse on stopping — consider this a long-term maintenance commitment.

Disclaimer: Educational information only. Tesamorelin is FDA-approved for HIV lipodystrophy — off-label use requires physician supervision and regular metabolic monitoring.

Honest Assessment

Editor's summary

Tesamorelin is the most clinically validated GHRH analogue for body composition. The Phase III evidence is genuinely strong — two RCTs, 740 patients, clear visceral fat reduction with a real lipid benefit. The DPP-4 resistance modification makes it pharmacologically superior to sermorelin in terms of durability and potency. For anyone with confirmed visceral adiposity and metabolic risk, this is the best-evidenced GHRH tool available.

The honest caveats: it requires maintenance (effects reverse), it can worsen insulin sensitivity, 56% develop antibodies, and it is expensive. The off-label application for non-HIV visceral fat is clinically rational but the evidence base outside the HIV population is limited. The antibody development finding is the most genuinely uncertain aspect of long-term use — the clinical significance remains unclear.

Verdict
"The gold standard GHRH analogue for visceral fat. Better evidence than sermorelin for body composition specifically, more stable than natural GHRH, and with a clear FDA trial base. Requires metabolic monitoring, is expensive, and is maintenance rather than curative — but the evidence is real."